We support pharmaceutical companies in the UK with brand discontinuation
Our aim is to provide a comprehensive and reliable service to ensure a smooth and efficient process to ensure products are de-listed from with primary care prescribing systems in a timely manner.
We work with medicines management teams from Integrated Care Boards (ICBs) to notify them of the update so they can cascade the information to healthcare professionals so patients are not negatively impacted.
We have supported medicines management teams to implement messaging of the discontinuation through prescribing systems, throughout the ICB.
Removal of older
brand from
drug tariff
dm+d
update
Reimbursement*
Clinical System Listings
*Pharmacists unable to get reimbursement on prescriptions of removed product
Discontinued brands remain accessible to prescribe on GP systems for up to 3 months after product removal from drug tariff
The implication
Wastes time for patients, where prescriptions are returned as the item is not available
Wastes time for GPs & prescribers, cancelling and re-creating prescriptions for the alternative
Wastes time for Pharmacists, returning and requesting alternative prescriptions
We understand that brand discontinuations by pharmaceutical companies can be a complex and challenging process. That’s why we provide a comprehensive and reliable service to ensure a smooth and efficient transition for both healthcare professionals and patients.
Our primary focus is on ensuring that the products are de-listed from primary care prescribing systems in a timely manner, preventing any negative impact on patient care. We work closely with medicines management teams from Integrated Care Boards (ICBs) to notify them of the updates and ensure that healthcare professionals are informed of any changes.
To ease the transition, we work with medicines management teams to support notification of the discontinuation through the prescribing systems, making sure that all stakeholders involved in patient care are aware of the situation and can take appropriate actions.
Our service is designed to provide peace of mind for pharmaceutical companies, healthcare professionals, and patients alike. With our expertise and commitment to excellence, we strive to make the brand discontinuation process as smooth and stress-free as possible.
Oberoi Workstreams
Mapping
Determine the predicted timelines for de-listing of the drug in the GP system
Information Review
Review the product information prior to submission to the NHS Business Services Authority
NHS Business Services Authority
Liaise with the NHS Business Services Authority on behalf of the client
Audit
Conduct regular audits of clinical systems listings to ensure alignment with predicted timelines
GP System Listing Confirmation
Obtain visual confirmation of the de-listing in the GP system to provide brand and sales teams with full visibility
Clinical System Providers
Liaise with clinical system providers to understand key factors that may impact timeline or discontinuation of the drug
Benefits
Increased Efficiency: Assists pharmaceutical companies streamline the de-listing process
Better Communication: By working with medicines management teams, we ensure healthcare professionals are notified of brand discontinuations in a timely and accurate manner. Preventing confusion for patients
Enhanced Reputation: Pharmaceutical companies can demonstrate their commitment to patient safety and continuity of care, building trust with patients and healthcare professionals
